{
    "clinical_study": {
        "@rank": "28434", 
        "arm_group": [
            {
                "arm_group_label": "Corn oil/olive oil", 
                "arm_group_type": "Experimental", 
                "description": "Corn oil 56 g per day for 21 days followed by olive oil 56 g for 21 days"
            }, 
            {
                "arm_group_label": "Olive Oil/Corn Oil", 
                "arm_group_type": "Experimental", 
                "description": "olive oil, 56g per day for 21 days followed by corn oil, 56 g for 21 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The objectives of this clinical trial are to assess the effects of dietary oils on blood\n      lipids and other aspects of the fasting lipoprotein profile in healthy men and women with\n      elevated cholesterol"
        }, 
        "brief_title": "Effects of The Effects of Dietary Oils on Fasting Lipoprotein Lipids", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hypercholesterolemia", 
        "condition_browse": {
            "mesh_term": "Hypercholesterolemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Fasting LDL-C level equal to or greater than 130 mg/dL and less than 200 mg/dL at\n             visit 1\n\n          -  Fasting triglycerides less than or equal to 350 mg/dL at visit 1\n\n        Exclusion Criteria:\n\n          -  Has coronary heart disease or coronary heart disease risk risk equivalent, such as\n             diabetes, atherosclerosis, etc\n\n          -  Taking lipid medications intended to alter the lipids profile, including but not\n             limited to statins, bile acid sequestrants, etc.\n\n          -  Uncontrolled hypertension (systolic greater than or equal to 160 mm Hg or diastolic\n             greater than or equal to 100 mm Hg)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "74 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "57", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01925716", 
            "org_study_id": "PRV-1303"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Corn oil/olive oil", 
                    "Olive Oil/Corn Oil"
                ], 
                "description": "corn oil 56 g/day for 21 days", 
                "intervention_name": "Corn oil", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Corn oil/olive oil", 
                    "Olive Oil/Corn Oil"
                ], 
                "description": "olive oil 56 g /day for 21 days", 
                "intervention_name": "Olive oil", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "cholesterol,LDL", 
            "vegetable oils", 
            "heart diseases"
        ], 
        "lastchanged_date": "August 19, 2013", 
        "number_of_arms": "2", 
        "official_title": "A Randomized Double Blind Controlled Crossover Trial to Assess the Effects of Dietary Oils on Fasting Lipoprotein Lipids", 
        "other_outcome": [
            {
                "measure": "High density lipoprotein cholesterol", 
                "safety_issue": "No", 
                "time_frame": "baseline (average of days -7 and 0) and the end of each treatment period [Treatment I average of days 19 and 21) and treatment II (average of days 19 and 21)]: patients are followed for an average of 11 weeks"
            }, 
            {
                "measure": "Non-HDL-Cholesterol", 
                "safety_issue": "No", 
                "time_frame": "baseline (average of days -7 and 0) and the end of each treatment period [Treatment I average of days 19 and 21) and Treatment II (average of days 19 and 21)]: patients are followed for an average of 11 weeks"
            }, 
            {
                "measure": "Triglycerides", 
                "safety_issue": "No", 
                "time_frame": "baseline (average of days -7 and 0) and the end of each treatment period [Treatment I average of days 19 and 21) and Treatment II (average of days 19 and 21)]: patients are followed for an average of 11 weeks"
            }, 
            {
                "measure": "Total cholesterol/HDL-C ratio", 
                "safety_issue": "No", 
                "time_frame": "baseline (average of days -7 and 0) and the end of each treatment period [Treatment I average of days 19 and 21) and Treatment II (average of days 19 and 21)]: patients are followed for an average of 11 weeks"
            }
        ], 
        "overall_official": {
            "affiliation": "Biofortis Clinical Research", 
            "last_name": "Kevin C Maki, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Low Density Lipoprotein cholesterol", 
            "safety_issue": "No", 
            "time_frame": "Time Frame: baseline (average days -7 and 0) and the end of each treatment period [Treatment 1 averages of days 19 and 21and Treatment II (average of days 19 and 21)]: patients are followed for an average of 11 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01925716"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "total cholesterol", 
            "safety_issue": "No", 
            "time_frame": "baseline (average of days -7 and 0) and the end of each treatment period [Treatment I average of days 19 and 21) and treatment II (average of days 19 and 21)]: patients are followed for an average of 11 weeks"
        }, 
        "source": "ACH Food Companies, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "PepsiCo Global R&D", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "ACH Food Companies, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}